Recent Updates
Recently added Catalysts
IMNM Positive Sentiment

Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026

Monday, October 26, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Immunome, Inc. presented new clinical data for its drug varegacestat at the 2026 ESMO Congress. The investigational gamma secretase inhibitor was highlighted in four presentations, including a rapid oral presentation. This data aims to support its development for treating desmoid tumors.

Market Sentiment Analysis

POSITIVE FACTORS

  • Immunome presented additional clinical data for varegacestat.
  • The data was featured in four presentations at ESMO 2026.
  • Varegacestat is an investigational, oral, once-daily gamma secretase inhibitor.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+27%
120-day peak, hindsight
Typical move
28.8%
average across 3 past catalysts
Cash runway
~23 mo
Low dilution risk
Lead asset
IM-1021
Phase 1 · Solid Malignancies

Full Press Release Details

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the presentation of additional clinical data for varegacestat, its investigational, oral, once-daily gamma secretase inhibitor, at the 2026 European Society for Medical Oncology (ESMO) Congress. The data were featured in four presentations, including a rapid oral presentation on patient-repo

Frequently Asked Questions

What is varegacestat?

Varegacestat is an investigational, oral, once-daily gamma secretase inhibitor developed by Immunome.

Where was the data presented?

Immunome presented additional clinical data for varegacestat at the 2026 ESMO Congress.

What tumors is it targeting?

The clinical data focuses on the treatment of desmoid tumors using varegacestat.

How many presentations were there?

The data was featured in four presentations, including a rapid oral presentation.

ShareAdd on Google
Tags: IMNM Immunome varegacestat desmoid tumors ESMO 2026 gamma secretase inhibitor
Last updated: Oct 26, 2026

Biotech snapshot

Cash runway
$520M liquidity · $21M/mo burn
~23 mo
Low dilution risk
Lead asset
IM-1021Phase 1
Solid Malignancies →

Catalyst track record

+27%
best trade around IMNM's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for IMNM.

See every catalyst's timing & PoA →